Alexander Muik
BioNTech (Germany)(DE)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Animal Virus Infections Studies, Virus-based gene therapy research, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research
Most-Cited Works
- → COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses(2020)2,020 cited
- → BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans(2021)818 cited
- → BNT162b vaccines protect rhesus macaques from SARS-CoV-2(2021)731 cited
- → Neutralizing Activity of BNT162b2-Elicited Serum(2021)631 cited
- → Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera(2021)554 cited
- → Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera(2022)383 cited
- → BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants(2021)379 cited
- → Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes(2022)218 cited
- → The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines(2022)201 cited
- → Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine(2023)175 cited